BRPF1 and hepatocellular carcinoma: Recent studies with GSK5959 (GSK6853 ortholog) have shown that BRPF1 inhibition can prevent HCC progression in cells and in mice, making these inhibitors possible therapeutic drugs for HCC treatment (Cheng et al., 2021).